C12Y 304/22055
Caspase-2
Official title: Caspase-2 (3.4.22.55)
C12Y304/22055 (Caspase-2) appears on 14 US grants and 31 published applications in this corpus.
Search patents in C12Y- Granted patents
- 14
- Published applications
- 31
- Assignees
- 15
- Inventors
- 55
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 1 | 0 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 1 |
| 2014 | 0 | 3 |
| 2015 | 2 | 3 |
| 2016 | 3 | 2 |
| 2017 | 1 | 3 |
| 2018 | 0 | 0 |
| 2019 | 0 | 2 |
| 2020 | 1 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 1 | 1 |
| 2024 | 1 | 2 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Caspase-2 variants4 Aug 2026US 12,698,486 B2Boehringer Ingelheim International GmbH
- Method of screening inhibitor of caspase activity by lipopolysaccharide12 Mar 2024US 11,926,860 B2Korea Institute of Science and Technology
- Compositions and methods for selective elimination and replacement of hematopoietic stem cells5 Sep 2023US 11,744,861 B2Poseida Therapeutics, Inc.
- Methods and compositions for nucleic acid integration6 Jul 2021US 11,053,271 B2The Regents of the University of California
- Double-stranded RNA compounds to CASP2 and uses thereof25 Feb 2020US 10,570,394 B2Quark Pharmaceuticals, Inc.
- Compositions and methods for selective elimination and replacement of hematopoietic stem cells11 Jul 2024US 2024/0226153 A9Poseida Therapeutics, Inc.
- Compositions and methods for selective elimination and replacement of hematopoietic stem cells25 Apr 2024US 2024/0131067 A1Poseida Therapeutics, Inc.
- Anti-idiotype compositions and methods of use thereof9 Nov 2023US 2023/0357436 A1Exuma Biotech Corp.
- Caspase-2 variants1 Dec 2022US 2022/0380739 A1Boehringer Ingelheim Rcv GmbH & Co KG
- Method of screening inhibitor of caspase activity by lipopolysaccharide14 Jul 2022US 2022/0220529 A1Korea Institute of Science and Technology
Most cited
By later US patents
- Antisense compounds which prevent cell death and uses thereof18US 5,929,042 AThe Trustees of Columbia University in the City of New York · 1999
- Methods of treating ischemia-reperfusion injury with siRNAs3US 9,446,062 B2Quark Pharmaceuticals, Inc. · 2016
- Altered human interleukin-1β convertase (ICE), NEDD-2, and C. elegans ced-3 polypeptides and uses therefor1US 6,939,850 B2Massachusetts Institute of Technology · 2005
- Method for the determination of botulinum neurotoxin biological activity1US 9,096,886 B2MERZ PHARMA GmbH & CO. KGaA · 2015